ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Baltimore, MD, USA:

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The st...

Enrolling
Ovarian Cancer
Drug: Gleolan

Phase 3

NX Development

Annapolis, Maryland, United States

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Baltimore, Maryland, United States and 125 other locations

cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

Genelux

Silver Spring, Maryland, United States and 23 other locations

(CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has...

Active, not recruiting
Stage III Ovarian Cancer AJCC V8
Stage IIIB Fallopian Tube Cancer AJCC V8
Biological: PRGN-3005 UltraCAR-T cells

Phase 1

Precigen

Bethesda, Maryland, United States and 1 other location

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Towson, Maryland, United States and 213 other locations

carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian...

Enrolling
Ovarian Cancer Stage 3
Ovarian Cancer Stage IV
Drug: Toripalimab-tpzi
Biological: NY-ESO-1 Peptide vaccine

Phase 2

Georgetown University
Georgetown University

Washington, District of Columbia, United States and 1 other location

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Glenn Dale, Maryland, United States and 46 other locations

(PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian ....

Active, not recruiting
Fallopian Tube Cancer
Ovarian Cancer
Drug: Niraparib
Drug: ZN-c3

Phase 1, Phase 2

K-Group Beta

Fairfax, Virginia, United States and 19 other locations

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Enrolling
Ovary Cancer
Ovarian Carcinoma
Drug: STRO-002
Drug: Bevacizumab

Phase 1

Sutro Biopharma

Fairfax, Virginia, United States and 5 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Baltimore, Maryland, United States and 176 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems